Literature DB >> 10398550

The development of a World Health Organisation international standard for islet cell antibodies: the aims and design of an international collaborative study.

A R Mire-Sluis1, R G Das, A Lernmark.   

Abstract

Islet cell antibodies (ICA) are a specific marker for Type 1 (insulin-dependent) diabetes mellitus. ICA are found in the serum of over 80% of newly diagnosed patients and the levels of ICA are directly of prognostic value. Standardisation of ICA and the uniform reporting of ICA levels in international units is critical to preclinical/clinical research and the development of assays for ICA as diagnostics, in particular for the differential diagnosis of late onset Type 1 and Type 2 diabetes. Proficiency studies carried out by the Immunology of Diabetes Workshops on Standardization have clearly shown that a single reference material, serum sample 673, obtained by Dr J. Ludvigsson, has significantly reduced inter- and intra-assay variability in the reporting of ICA levels. Nevertheless, this material is a frozen serum of limited shelf-life and is difficult to distribute on a worldwide and routine basis. Therefore, the Immunology of Diabetes Workshop Standardization Committee and the Juvenile Diabetes Foundation International requested that the National Institute for Biological Standards and Control (NIBSC) organise an international collaborative study to compare the activities of lyophilised, stable ICA preparations. In addition, the purpose was to investigate if sample 673 could also serve as a standard for GAD65 and IA-2 antibodies. Twenty participants in eight countries have been recruited to the study. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10398550     DOI: 10.1002/(sici)1520-7560(199901/02)15:1<72::aid-dmrr11>3.0.co;2-g

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  5 in total

1.  An AP-3-dependent mechanism drives synaptic-like microvesicle biogenesis in pancreatic islet beta-cells.

Authors:  Arthur T Suckow; Branch Craige; Victor Faundez; William J Cain; Steven D Chessler
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-05-04       Impact factor: 4.310

2.  Classifying diabetes according to the new WHO clinical stages.

Authors:  E Lindholm; E Agardh; T Tuomi; L Groop; C D Agardh
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

Review 3.  A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease.

Authors:  Michael G Agadjanyan; Nikolai Petrovsky; Anahit Ghochikyan
Journal:  Alzheimers Dement       Date:  2015-07-17       Impact factor: 21.566

4.  Common variants in the TCF7L2 gene help to differentiate autoimmune from non-autoimmune diabetes in young (15-34 years) but not in middle-aged (40-59 years) diabetic patients.

Authors:  E Bakhtadze; C Cervin; E Lindholm; H Borg; P Nilsson; H J Arnqvist; J Bolinder; J W Eriksson; S Gudbjörnsdottir; L Nyström; C-D Agardh; M Landin-Olsson; G Sundkvist; L C Groop
Journal:  Diabetologia       Date:  2008-10-07       Impact factor: 10.122

5.  Conformation-dependent GAD65 autoantibodies in diabetes.

Authors:  D Luo; L K Gilliam; C Greenbaum; L Bekris; C S Hampe; T Daniels; W Richter; S M Marcovina; O Rolandsson; M Landin-Olsson; I Kockum; A Lernmark
Journal:  Diabetologia       Date:  2004-09-08       Impact factor: 10.122

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.